narlumosbart   Click here for help

GtoPdb Ligand ID: 13084

Synonyms: Jinlitai® | JMT-103 | JMT103
Approved drug
narlumosbart is an approved drug (China (2023))
Compound class: Antibody
Comment: Narlumosbart (JMT103) is a fully human IgG4κ anti-RANKL (receptor activator of nuclear factor kappa-Β ligand) monoclonal antibody. It blocks the RANK/RANKL protein-protein interaction and thereby reduces pathological osteoclastogenesis in bone cancer.
No information available.
Summary of Clinical Use Click here for help
Narlumosbart (JMT103) was advanced as a clinical candidate for the treament of bone disorders, including osteoporosis, bone metastases from solid tumours [2] and giant cell tumor of bone (GCTB). Narlumosbart was first approved in China in September 2023, for the bone cancer indication [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05278338 Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis Phase 2 Interventional Shanghai JMT-Bio Inc.
NCT05813665 A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone Phase 3 Interventional Shanghai JMT-Bio Inc.
NCT03550508 Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors Phase 1 Interventional Shanghai JMT-Bio Inc. 2